Factors that influence the bleeding phenotype in severe hemophilic patients

Blood Coagulation and Fibrinolysis

Volumn 24, Issue 7, 2013, Pages 683-690

  Rendo, Pablo ^a   Shafer, Frank ^a   Korth Bradley, Joan M ^a   Sivamurthy, Krupa ^a   Korin, Jorge ^b  

^a PFIZER INC   (United States)

^b Consultorios Hematológicos ^*  (Argentina)

Author keywords

blood coagulation disorder; hemophilia A; hemophilia B; inherited

Indexed keywords

D DIMER; HEME; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MYC PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN MDM2; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; BLEEDING TENDENCY; BLOOD CLOTTING; BODY WEIGHT; CYTOKINE PRODUCTION; HEMOPHILIA A; HEMOPHILIA B; HEMOPHILIC ARTHROPATHY; HEMOSTASIS; HUMAN; NONHUMAN; PHENOTYPE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; RANGE OF MOTION; REVIEW; SEASONAL VARIATION; THROMBOCYTE ACTIVATION;

HEMOPHILIA A; HEMORRHAGE; HUMANS;

EID: 84885183560     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3283614210     Document Type: Review

References (73)

1. World Federation of Hemophilia. Report on the Annual Global Survey 2010.
2. Montreal, Quebec, Canada: World Federation of Hemophilia. http://www1.wfh.org/publications/files/pdf-1427.pdf [Accessed 4 September 2012].
3. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet 2003; 361:1801-1809. (Pubitemid 36638432)
4. Bleeding disorders: FAQs. 2009; Washington, DC: Hemophilia Federation of America. http://hemophiliafed.org/who-are-we/about-bleedingdisorders/bleeding- disorders-faqs/[Accessed 22 October 2012].
5. Nagel K, Walker I, Decker K, Chan AK, Pai MK. Comparing bleed frequency and factor concentrate use between haemophilia A and B patients. Haemophilia 2011; 17:872-874.
6. Tagariello G, Iorio A, Santagostino E, Morfini M, Bisson R, Innocenti M, et al. Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders. Blood 2009; 114:779-784.
7. Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357:535-544. (Pubitemid 47236278)
8. van den Berg HM, Fischer K, Mauser-Bunschoten EP, Beek FJ, Roosendaal G, van der Bom JG, Nieuwenhuis HK. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001; 112:561-565. (Pubitemid 32222823)
9. Gringeri A, Lundin B, von MS, Mantovani L, Mannucci PM. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9:700-710.
10. White GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85:560. (Pubitemid 32233035)
11. Den Uijl IE, Mauser Bunschoten EP, Roosendaal G, Schutgens RE, Biesma DH, Grobbee DE, Fischer K. Clinical severity of haemophilia A: does the classification of the 1950 s still stand? Haemophilia 2011; 17:849-853.
12. Jayandharan GR, Srivastava A, Srivastava A. Role of molecular genetics in hemophilia: from diagnosis to therapy. Semin Thromb Hemost 2012; 38:64-78.
13. Ahnstrom J, Berntorp E, Lindvall K, Bjorkman S. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia 2004; 10:689-697. (Pubitemid 40028584)
14. Jenkins PV, Collins PW, Goldman E, McCraw A, Riddell A, Lee CA, Pasi KJ. Analysis of intron 22 inversions of the factor VIII gene in severe hemophilia A: implications for genetic counseling. Blood 1994; 84:2197-2201. (Pubitemid 24296378)
15. Higuchi M, Antonarakis SE, Kasch L, Oldenburg J, Economou-Petersen E, Olek K, et al. Molecular characterization of mild-to-moderate hemophilia A: detection of the mutation in 25 of 29 patients by denaturing gradient gel electrophoresis. Proc Natl Acad Sci U S A 1991; 88:8307-8311. (Pubitemid 21915345)
16. Jayandharan GR, Nair SC, Poonnoose PM, Thomas R, John J, Keshav SK, et al. Polymorphism in factor VII gene modifies phenotype of severe haemophilia. Haemophilia 2009; 15:1228-1236.
17. van Dijk K, van der Bom JG, Fischer K, Grobbee DE, van den Berg HM. Do prothrombotic factors influence clinical phenotype of severe haemophilia A review of the literature. Thromb Haemost 2004; 92:305-310. (Pubitemid 39172311)
18. Bauer KA. Hypercoagulable states. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Silberstein LE, McGlave P, Heslop H, editors. Hematology: basic principles and practices, 5th ed. Philadelphia, PA: Churchill Livingstone; 2008. pp. 2021-2042.
19. Dykes AC, Walker ID, McMahon AD, Islam SI, Tait RC. A study of Protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state. Br J Haematol 2001; 113:636-641. (Pubitemid 32524382)
20. Tait RC, Walker ID, Reitsma PH, Islam SI, McCall F, Poort SR, et al. Prevalence of protein C deficiency in the healthy population. Thromb Haemost 1995; 73:87-93.
21. Wells PS, Blajchman MA, Henderson P, Wells MJ, Demers C, Bourque R, McAvoy A. Prevalence of antithrombin deficiency in healthy blood donors: a cross-sectional study. Am J Hematol 1994; 45:321-324. (Pubitemid 24109908)
22. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de RH, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369:64-67. (Pubitemid 24144355)
23. Voorberg J, Roelse J, Koopman R, Buller H, Berends F, ten Cate JW, et al. Association of idiopathic venous thromboembolism with single pointmutation at Arg506 of factor V. Lancet 1994; 343:1535-1536.
24. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346:1133-1134.
25. Koster T, Rosendaal FR, de RH, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342:1503-1506. (Pubitemid 23362165)
26. Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 1994; 343:1361-1362. (Pubitemid 24162587)
27. Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82:1989-1993. (Pubitemid 23293978)
28. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330:517-522. (Pubitemid 24058953)
29. Prothrombin G20210A mutation, blood. 2012; MayoMedical Laboratories. http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/ 81742 [Accessed 4 September 2012].
30. Perry DJ. Hyperhomocysteinaemia. Baillieres Best Pract Res Clin Haematol 1999; 12:451-477. (Pubitemid 30312622)
31. Krajinovic M, Lamothe S, Labuda D, Lemieux-Blanchard E, Theoret Y, Moghrabi A, Sinnett D. Role of MTHFR genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Blood 2004; 103:252-257. (Pubitemid 38029946)
32. Shetty S, Ghosh K. Reduced clinical severity in a mutationally well characterized cohort of severe hemophilia with associated thrombophilia. Am J Clin Pathol 2008; 130:84-87.
33. Ghosh K, Shetty S, Mohanty D. Milder clinical presentation of haemophilia A with severe deficiency of factor VIII as measured by one-stage assay. Haemophilia 2001; 7:9-12. (Pubitemid 32162191)
34. Ahmed R, Kannan M, Choudhry VP, Saxena R. Does the MTHFR 677T allele alter the clinical phenotype in severe haemophilia A? Thromb Res 2003; 109:71-72. (Pubitemid 36385050)
35. Lee DH, Walker IR, Teitel J, Poon MC, Ritchie B, Akabutu J, et al. Effect of the factor V Leiden mutation on the clinical expression of severe hemophilia A. Thromb Haemost 2000; 83:387-391. (Pubitemid 30148349)
36. Nowak-Gottl U, Escuriola C, Kurnik K, Schobess R, Horneff S, Kosch A, et al. Haemophilia and thrombophilia. What do we learn about combined inheritance of both genetic variations? Hamostaseologie 2003; 23:36-40. (Pubitemid 36197307)
37. Kurnik K, Kreuz W, Horneff S, During C, Schobess R, Bidlingmaier C, et al. Effects of the factor V G1691A mutation and the factor II G20210A variant on the clinical expression of severe hemophilia A in children-results of a multicenter studys. Haematologica 2007; 92:982-985. (Pubitemid 350144247)
38. Escuriola Ettingshausen C, Halimeh S, Kurnik K, Schobess R, Wermes C, Junker R, et al. Symptomatic onset of severe hemophilia A in childhood is dependent on the presence of prothrombotic risk factors. Thromb Haemost 2001; 85:218-220. (Pubitemid 32140563)
39. Di Perna C, Franchini M, Riccardi F, Rivolta GF, Angeri F, Tagliaferri A. Association between haemophilia and inherited thrombophilia: a single centre survey. Haemophilia 2011; 17:161-162.
40. Schulman S, Eelde A, Holmstrom M, Stahlberg G, Odeberg J, Blomback M. Validation of a composite score for clinical severity of hemophilia. J Thromb Haemost 2008; 6:1113-1121. (Pubitemid 351859120)
41. Tuten H, Cam H, Ozdemir N, Bezgal F, Buyru N, Zulfikar B, Celkan T. Effect of prothrombotic mutations on factor consumption in children with hemophilia. Clin Appl Thromb Hemost 2012 [Epub ahead of print].
42. Grunewald M, Siegemund A, Grunewald A, Konegan A, Koksch M, Griesshammer M. Paradoxical hyperfibrinolysis is associated with a more intensely haemorrhagic phenotype in severe congenital haemophilia. Haemophilia 2002; 8:768-775. (Pubitemid 35446629)
43. van Bladel ER, Roest M, de Groot PG, Schutgens RE. Up-regulation of platelet activation in hemophilia A. Haematologica 2011; 96:888-895.
44. Teyssandier M, Delignat S, Rayes J, Bryckaert M, Jandrot-Perrus M, Kaveri SV, Lacroix-Desmazes S. Activation state of platelet in experimental severe hemophilia A. Haematologica 2012; 97:1115-1116.
45. Van Meegeren M. Update on pathogenesis of the bleeding joint: an interplay between inflammatory and degenerative pathways. Haemophilia 2010; 16 (Suppl 5):121-123.
46. Jansen NW, Roosendaal G, Lafeber FP. Understanding haemophilic arthropathy: an exploration of current open issues. Br J Haematol 2008; 143:632-640.
47. Cruz E, Porto G, Morais S, Campos M, de SM. HFE mutations in the pathobiology of hemophilic arthropathy. Blood 2005; 105:3381-3382.
48. Carroll GJ, Breidahl WH, Bulsara MK, Olynyk JK. Hereditary hemochromatosis is characterized by a clinically definable arthropathy that correlates with iron load. Arthritis Rheum 2011; 63:286-294.
49. Wagener FA, Toonen EJ, Wigman L, Fransen J, Creemers MC, Radstake TR, et al. HMOX1 promoter polymorphism modulates the relationship between disease activity and joint damage in rheumatoid arthritis. Arthritis Rheum 2008; 58:3388-3393.
50. Roosendaal G, Vianen ME, Wenting MJ, van Rinsum AC, van den Berg HM, Lafeber FP, Bijlsma JW. Iron deposits and catabolic properties of synovial tissue from patients with haemophilia. J Bone Joint Surg Br 1998; 80:540-545.
51. Ovlisen K, Kristensen AT, Jensen AL, Tranholm M. IL-1 beta, IL-6, KC and MCP-1 are elevated in synovial fluid from haemophilic mice with experimentally induced haemarthrosis. Haemophilia 2009; 15:802-810.
52. Klimiuk PA, Goronzy JJ, Bjor NJ, Beckenbaugh RD, Weyand CM. Tissue cytokine patterns distinguish variants of rheumatoid synovitis. Am J Pathol 1997; 151:1311-1319. (Pubitemid 27479761)
53. Vinasco J, Beraun Y, Nieto A, Fraile A, Mataran L, Pareja E, Martin J. Polymorphism at the TNF loci in rheumatoid arthritis. Tissue Antigens 1997; 49:74-78.
54. Lard LR, van Gaalen FA, Schonkeren JJ, Pieterman EJ, Stoeken G, Vos K, et al. Association of the -2849 interleukin-10 promoter polymorphism with autoantibody production and joint destruction in rheumatoid arthritis. Arthritis Rheum 2003; 48:1841-1848. (Pubitemid 36828678)
55. Jansen NW, Roosendaal G, Hooiveld MJ, Bijlsma JW, van Roon JA, Theobald M, Lafeber FP. Interleukin-10 protects against blood-induced joint damage. Br J Haematol 2008; 142:953-961.
56. Hakobyan N, Kazarian T, Jabbar AA, Jabbar KJ, Valentino LA. Pathobiology of hemophilic synovitis I: overexpression of mdm2 oncogene. Blood 2004; 104:2060-2064. (Pubitemid 39297857)
57. Wen FQ, Jabbar AA, Chen YX, Kazarian T, Patel DA, Valentino LA. c-myc proto-oncogene expression in hemophilic synovitis: in vitro studies of the effects of iron and ceramide. Blood 2002; 100:912-916. (Pubitemid 34832617)
58. Acharya SS, Kaplan RN, Macdonald D, Fabiyi OT, Dimichele D, Lyden D. Neoangiogenesis contributes to the development of hemophilic synovitis. Blood 2011; 117:2484-2493.
59. Drouart M, Saas P, Billot M, Cedoz JP, Tiberghien P, Wendling D, Toussirot E. High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathies. Clin Exp Immunol 2003; 132:158-162. (Pubitemid 36418919)
60. Sone H, Sakauchi M, Takahashi A, Suzuki H, Inoue N, Iida K, et al. Elevated levels of vascular endothelial growth factor in the sera of patients with rheumatoid arthritis correlation with disease activity. Life Sci 2001; 69:1861-1869. (Pubitemid 32835268)
61. Benbassat J. Periodic haemorrhages in haemophilia A. BMJ 1971; 3:771.
62. Hoffman M, Harger A, Lenkowski A, Hedner U, Roberts HR, Monroe DM. Cutaneous wound healing is impaired in hemophilia B. Blood 2006; 108:3053-3060.
63. Ollivier V, Chabbat J, Herbert JM, Hakim J, de PD. Vascular endothelial growth factor production by fibroblasts in response to factor VIIa binding to tissue factor involves thrombin and factor Xa. Arterioscler Thromb Vasc Biol 2000; 20:1374-1381. (Pubitemid 30262941)
64. Jazwa A, Loboda A, Golda S, Cisowski J, Szelag M, Zagorska A, et al. Effect of heme and heme oxygenase-1 on vascular endothelial growth factor synthesis and angiogenic potency of human keratinocytes. Free Radic Biol Med 2006; 40:1250-1263.
65. Linde P, Syrbe G. [Meteorologic effects on hemorrhagic diathesis in hemophilia. 2. Weather effects on hemophilia with special reference to the atmospheric temperature-humidity complex]. Z Gesamte Inn Med 1990; 45:659-662.
66. Linde P, Syrbe G. [Recommendations for a medical-meteorologic prognosis for hemophilia]. Folia Haematol Int Mag Klin Morphol Blutforsch 1990; 117:631-634.
67. Rainsford SG, Hall A. A three-year study of adolescent boys suffering from haemophilia and allied disorders. Br J Haematol 1973; 24:539-551.
68. van Dijk K, Fischer K, van der Bom JG, Mauser-Bunschosten EP, Roosendaal G, Marijke van den Berg H. Variability in bleeding pattern of severe hemophilia [abstract]. Blood 2004; 104:3094.
69. Shafer F, Smith L, Rendo P, Carr M. Lack of seasonal variation in bleeding risk in patients with hemophilia B [poster]. Annual Meeting of the National Hemophilia Foundation, Chicago, IL, 10-12 November 2011.
70. Tiktinsky R, Falk B, Heim M, Martinovitz U. The effect of resistance training on the frequency of bleeding in haemophilia patients: a pilot study. Haemophilia 2002; 8:22-27. (Pubitemid 34257915)
71. Majumdar S, Ahmad N, Karlson C, Morris A, Iyer R. Does weight reduction in haemophilia lead to a decrease in joint bleeds? Haemophilia 2012; 18:e82-e84.
72. Soucie JM, Wang C, Siddiqi A, Kulkarni R, Recht M, Konkle BA. The longitudinal effect of body adiposity on joint mobility in young males with Haemophilia A. Haemophilia 2011; 17:196-203.
73. LaBaw W. The use of hypnosis with hemophilia. Psychiatr Med 1992; 10:89-98.